Results 61 to 70 of about 23,616 (164)

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. [PDF]

Biologics
Patel R, Brooks D, Gorseth E, Moate R, Hofherr A, Kell C, Luporini Saraiva G, Pandya H, Jenkins M, Psallidas I.   +9 more
europepmc   +1 more source

Deep Learning Improves Sensitivity to Change in Sinus Computed Tomography: Evidence From Two Randomized Controlled Trials. [PDF]

Int Forum Allergy Rhinol
MacKay JW, Nordenmark LH, Necander S, Cohen D, Werkström V, Jison M, Sood R, Lynch D, Humphries SM.   +8 more
europepmc   +1 more source

Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P-gp Inhibitor. [PDF]

J Clin Pharmacol
Eriksson AL, Karsanji D, Shi AH, Parkinson J, Heijer M, Austin E, Lindmark B, Vedin-Nilsson C, Hartleib-Geschwindner J, Leonsson-Zachrisson M, Ericsson H.   +10 more
europepmc   +1 more source

Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)

International Journal of COPD
Clementine Nordon,1 Donna Carstens,2 Malin Fagerås,3 Hana Müllerová,1 Phani S Veeranki,4 João André Alves,3 Hayley D Germack,2 Timothy L Barnes,4 Meredith C McCormack5 1Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK;
Nordon C, Carstens D, Fagerås M, Müllerová H, Veeranki PS, Alves JA, Germack HD, Barnes TL, McCormack MC   +8 more
doaj  

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations. [PDF]

BMJ Open Respir Res
Watz H, Sciurba FC, Bonini M, Yañez A, Bourdin A, Zheng J, De Soyza A, Janssens W, van den Berge M, Xu JF, Saraiva GL, Jenkins M, Jimenez E, Lofdahl M, Li J, Mikosz M, Kishishita N, Jackson S, Johnson S, Patel R, Fagerås M, Psallidas I.   +21 more
europepmc   +1 more source

Reply to: Malik MMUD on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). [PDF]

Int Forum Allergy Rhinol
Mullol J, Han JK, Laidlaw TM, Hopkins C, Peters AT, Pfaar O, Desrosiers M, Lee SE, Lane AP, Chen C, Chon Y, Ponnarambil SS, Foster A, Lindsley AW, Ambrose CS.   +14 more
europepmc   +1 more source

Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes. [PDF]

Nature
Zou XZ, Hu F, Lou H, Burren OS, Li X, Megy K, Wheeler E, Wu Q, Atanur SS, Karpinski M, Loesch D, Fairhurst-Hunter Z, Deevi SVV, Oerton E, Wen S, Jiang X, Salvoro C, Mitchell J, Nag A, Hollis B, O'Neill A, AstraZeneca Genomics Initiative, Harrow J, MacArthur S, Wasilewski S, O'Dell S, Tian L, Smith KR, Del Angel G, Fabre M, Dhindsa RS, Wang Q, Petrovski S, Carss K.   +33 more
europepmc   +1 more source

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Scientific Reports, 2022
Maohua Li, Rongqing Zhao, Jianxin Chen, Wenzhi Tian, Chenxi Xia, Xudong Liu, Yingzi Li, Song Li, Hunter Sun, Tong Shen, Wenlin Ren, Le Sun   +11 more
doaj   +1 more source

Dual-Stimuli Responsive Poly(N-acryloyl glycine) Microgels: Investigation of Network Structures and Application for Loading and Release of Biologics. [PDF]

Small
Dursun Y, Aydin B, Lamsal B, Ceylan D, Saalwächter K, Wischke C.   +5 more
europepmc   +1 more source

Budesonide/formoterol fumarate dihydrate <i>versus</i> budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study. [PDF]

ERJ Open Res
Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Chami H, Armengol C, Daoud SZ, Nauclér E, Bowen K, Megally A, Sobande O, Patel M.   +12 more
europepmc   +1 more source